drugset / Trial / NCT00582673

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

NCT00582673

Phase 2 Completed 31 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.

Timeline

Start
2007-10
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule 25 mg Oral
Subject Mavoglurant Small molecule 150 mg Oral

Indications